A synthetic peptide that contains a Semliki Forest virus (SFV) B cell epitope, located at amino acid positions 240 to 255 of the E2 protein, and an SFV T helper (Th) cell epitope, located at positions 137 to 151 of the E2 protein, evoked high titres of SFV-reactive antibodies in H-2 d mice. Although the peptide-induced antibodies did not neutralize SFV in vitro, 70 to 100% of the peptide-immunized mice were protected against SFV, even when viral challenge was presented 4 months after immunization. The protection could be transferred by anti-peptide serum, indicating that antibodies were responsible for the protection. When the Th cell epitope of this protective peptide was replaced by an influenza virus Th cell epitope or by another SFV Th cell epitope, the resulting peptides induced lower non-neutralizing SFV-reactive antibody titres and protected a correspondingly lower percentage of mice (50% and 30%, respectively). A peptide with the same Th cell epitope as the best protective peptide but with a less effective SFV B cell epitope protected only 33% of the mice. These results indicate that protection against SFV by a synthetic peptide is primarily dependent on its ability to induce adequate amounts of antibodies with relevant specificity and sufficient affinity; the ability to induce a relevant (SFV-specific) T memory response played only a minor role in protection.
Introduction
The use of synthetic peptides as vaccines offers considerable advantages over conventional vaccines in terms of safety, purity, stability, availability and cost (Stewart & Howard, 1987) . The vaccine efficacy of synthetic peptides designed for antibody-mediated protection, however, is usually lower than that of conventional vaccines, since B cell epitopes are generally conformational structures on the surface of the (protein) antigen (Benjamin et al., 1984; Laver et al., 1990) that cannot be represented by short peptides. Nevertheless anti-peptide antibodies can sometimes be protective and in those cases a peptide vaccine may be feasible.
Peptide immunogens induce no secondary antibody responses unless they contain both B cell epitopes and T helper (Th) cell epitopes. The Tn activity can be provided by a carrier protein that will inevitably evoke an (undesirable) anti-carrier response. Fully synthetic peptide vaccines will be less liable to evoke undesirable side-effects, since they would induce only a very limited set of antibodies against predefined B cell epitopes (Francis & Clarke, 1989) . Moreover, synthetic peptides that contain both a B and a Th cell epitope derived from the same pathogen are postulated to be more effective as vaccines against that pathogen than either free or 0001-0853 O 1992 SGM carrier-conjugated peptides that contain only foreign T h cell epitopes, because they will prime a T memory response relevant to the pathogen (Milich et al., 1988; Hosmalin et al., 1991) .
To test this hypothesis, the immunogenic and protective properties of five potential vaccine peptides were compared, using Semliki Forest virus (SFV) infection of mice as a model system to monitor protection. Each peptide contained a B and a T h cell epitope. Two different linear B cell epitopes of SFV were used as were three different Th cell epitopes, two of SFV (A. Snijders et al., unpublished results) and one of influenza virus (Hackett et al., 1985) . One of the two linear B cell epitopes of SFV was shown previously to protect mice against SFV by evoking (when conjugated to a carrier) high titres of non-neutralizing antibodies, whereas the other evoked low titres of SFV-reactive antibodies and was only marginally protective (Snijders et al., 1991) . The role of the Th cell epitopes and the anti-peptide antibodies in the observed protection was assessed.
Methods
Synthetic peptides. Peptides were either synthesized by E. Freund (Hubrecht Laboratory, Utrecht, The Netherlands) as described (Snijders et al., 1991) or (peptides e and f) by Waters, Millipore on a Milligen/Biosearch 9050 Peptide Synthesizer. The amino acid sequences of the peptides were derived from the nucleotide sequence of the prototype strain ofSFV (Garoffet al., 1980) or the A/PR/8/34 strain of influenza virus (Hackett et al., 1983) . Peptide purity was assessed by HPLC. Peptide h was a kind gift from Dr M. J. M. Koolen (Koolen et al., 1990) .
Immunization of mice.
Male BALB/c and DBA/2 mice aged 8 to 10 weeks were obtained from lffa Credo. Groups of mice were immunized subcutaneously with 50 p.g of free synthetic peptide mixed with 50 ktg of the adjuvant Quil A (Superfos Biosector) in a volume of 100 ktl PBS. One booster injection was given after 5 to 6 weeks. Sera were generally obtained 2 weeks after the booster.
Antibody titres. Antibody titres were determined by indirect ELISA with horseradish peroxidase-coupled goat anti-mouse IgG on coated peptide or prototype SFV-infected L cells as described (Snijders et al., 1991) . The titre was defined as -log~o of the highest serum dilution that resulted in an extinction value obtained for a specific coat (homologous peptide or SFV-infected cells) that was > 0.20 and at least 0-10 higher than the extinction obtained for the corresponding control coat (heterologous peptide or uninfected L cells).
Neutralization assay. Neutralization titres of sera were determined in a neutralizaton enzyme immunoassay as described (van Tiel et al., 1986) . Titre was defined as -log10 of the highest serum dilution that resulted in a 25~ reduction of the extinction, which is similar to a 50~ plaque reduction.
Protection studies. Groups of peptide-immunized mice or corresponding control mice were challenged intraperitoneally 4 weeks after the last immunization with 16 p.f.u, of virulent SFV (equivalent to 10 LDso for naive 10 to 12 week old male BALB/c mice). To quantify protection, mice were observed for 21 days.
Passive protection by antipeptide sera was studied in groups of BALB/c mice that had been injected intravenously with 0.5 ml immune or control BALB/c serum and challenged 24 h later with 16 p.f.u, of SFV.
Results

Peptide-induced protection
To determine whether peptides with an SFV Th cell epitope are more effective than peptides with a foreign :~ Neutralization titre (as defined in Methods) of pooled (prechallenge) sera of each group of mice. The neutralization titre of individual sera obtained 3 weeks after SFV challenge from the surviving mice varied from 1.8 to >2-1 for peptide e-immunized mice, from 0.3 to > 2.1 for peptide J:immunized mice and from 0.9 to > 2-1 for peptide g-immunized mice.
§ Survival percentages were combined results of two to six experiments. The IgG titres obtained in these different experiments varied by 0.5 or less from the presented values; n, total number of mice.
II .,or, Not tested.
Th cell epitope in protection against SFV, the immunogenic and protective properties of different synthetic peptides were compared. These peptides contain previously identified SFV B cell epitopes (Snijders et al., 1991) and H-2a-restricted Th cell epitopes of either SFV (A. Snijders et al., unpublished results) or influenza virus (Hackett et al., 1985) . The amino acid sequences of the peptides used in this study are presented in Table 1 , as well as their ability to evoke SFV-specific antibodies. All five peptides that contain a B and a Th cell epitope were immunogenic in BALB/c mice as indicated by their ability to evoke antipeptide antibodies (Table 2 ). Only * Donor sera were either pooled sera obtained from the same groups of six BALB/c mice used for the titration data in Table 2 or from groups of BALB/c mice immunized in the same way.
t Titre (determined as in Table 2 ) of pooled sera from two groups of six mice obtained 24 h after transfer. peptides e,fand g evoked antibodies that reacted to SFV. These three peptides contain the same SFV B cell epitope, but different T h cell epitopes. Peptide f, containing an SFV T h cell epitope, evoked higher anti-SFV IgG titres than did peptide g which contains an influenza virus Th cell epitope, whereas peptide e, containing another SFV T h cell epitope, evoked lower anti-SFV titres than did peptide g. None of the antipeptide sera neutralized the virus in vitro (data not shown). The protection against SFV induced by peptides e, fand g in BALB/c mice correlated well with the anti-SFV IgG titre ( Table 2 ), indicating that protection was mediated by the peptide-induced antibodies. However, peptide c, containing the same Th cell epitope as peptidef in addition to a less effective B cell epitope, was also, though only partially, protective. Mice immunized with peptide c showed a survival rate of 33 ~ compared to 14~ for the corresponding control mice, whereas SFVspecific antibodies were hardly detectable in their sera (anti-SFV IgG titre of individual sera ~<2.0). This finding indicated that priming a T memory response to SFV may contribute to protection against SFV but will by itself provide no more than partial protection.
Protection by antipeptide antibodies
Protection of non-immunized mice that had received serum from mice immunized with peptidefrevealed that protection was indeed antibody-mediated (Table 3 ). The lack of protection of mice that had received serum from mice immunized with peptide g indicated that the anti-SFV IgG titre may be rather critical. Protection of DBA/2 mice, which are deficient in the complement component C5, showed that protection could be obtained independently of the terminal route of the complement system (Table 4) .
To test how an increased time interval between 
86 (7) 12.0 g 3.5-3-0-3.0 14 (7) 6-3 * Titres (as defined in Methods) of pooled sera from six mice obtained respectively 2 weeks, 2 months and 4 months after the last immunization.
t Mean survival time of non-surviving mice in days.
immunization and challenge affects the protective capacity of peptidesfand g, peptide-immunized BALB/c mice were challenged 4 months, instead of the usual 4 weeks, after the last immunization. The IgG titres in both groups of mice decreased threefold after 4 months. The threefold decrease in IgG titre was apparently enough to abolish protection of mice immunized with peptide g, but the IgG titre after immunization with peptidefwas so high that even after 4 months the (log 1 o) anti-SFV antibody titre was still 3-5, high enough to confer protection (Table 5) . These results confirm the superiority of peptide f over peptide g in inducing antibodies that cross-react with SFV and are relevant in protection. The protection of mice immunized with peptide c having anti-SFV IgG titres that are too low for protection to be expected (Table 2) indicates that there may be a protective effect of priming a T memory response to SFV by the SFV T h cell epitope of peptides c andf This protection was however only marginal (33 ~) compared to the protection that can be obtained after immunization with peptidef(68~) or after administration of antiserum to peptide f (50~).
Cross-reactivity of antipeptide antibodies
Functional B cell epitopes are always exposed at the surface of the immunogen. In a synthetic peptide all regions are exposed, including those which are hidden in the intact protein from which the peptide is derived. .5 2.5 3.5 <2.0 c 3-5 > 3.5 < 2-0 2-5 f < 2-0 3-0 4-0 4-0 4-0 < 2-0 g <2.0 3.5 3.5 3.5 2-5 * Titre (as defined in Methods) determined for pooled sera of each group of six mice by indirect ELISA on coated peptide. Sera raised to peptides b and c and those to peptides fand g were measured in two separate experiments.
A. Snijders and others
t Peptide h contained the same influenza virus T h cell epitope as peptide g and a B cell epitope of mouse hepatitis virus (Koolen et al., 1990) .
When peptides are used as immunogens, these previously hidden regions may start to function as B cell epitopes and evoke antibodies that bind to the peptide and to the unfolded protein but not to the native form of the original protein. To determine whether peptides representing B and T cell epitopes will often evoke antibodies to regions outside their predefined B cell epitope, the specificities of peptide-induced antibodies were analysed in detail. Antisera raised against peptides b, c, fand g in BALB/c mice were tested for their crossreactivity with other partially overlapping peptides. All four antipeptide sera were found to contain not only antibodies that reacted with other peptides containing the same predefined B cell epitope, but also antibodies that reacted with peptides that share only the predefined T cell epitope with the immunizing peptide (Table 6) . Antiserum raised to peptide b had an even higher antibody titre in response to peptide e than peptide c, although peptide b shares its B cell epitope with peptide c and its Th cell epitope with peptide e. This finding indicates that peptide b evoked a stronger antibody response to its predefined T cell than to its predefined B cell epitope. Antibodies to peptides c, f and g were mainly, though not exclusively, directed to the predefined B cell epitope within each of these peptides. Our results illustrate how common the capacity of synthetic peptides is to induce antibodies that react with the peptide (Table 6 ) but will not react with the native protein. These antibodies may cause misleading results because they also react with unfolded protein, but will not be relevant in protection.
Discussion
In this study, the immunogenic and protective properties of different synthetic peptides were compared. One of these peptides, peptide f, containing both a B and a Th celt epitope of SFV proved the most effective both in the induction of SFV-reactive antibodies and in protection. The peptide evoked high titres of non-neutralizing SFVreactive antibodies and protected 70 to 100 % of the mice. The protection induced by peptidefcould be transferred to naive mice by serum, indicating that antibodies were responsible for the protection.
The mechanisms of protection by non-neutralizing antibodies can be those involving binding of the antibodies to virus-infected cells, such as antibodydependent cell-mediated cytotoxicity, antibody-dependent complement-mediated cytotoxicity (ADCMC) or retardation of viral growth, as well as mechanisms involving binding to infectious viral particles, like aggregation and enhanced uptake of opsonized viral particles by phagocytes. Peptidefprotected BALB/c and C5-deficient DBA/2 mice equally efficiently against SFV, showing that the protection was independent of the terminal route of complement. Therefore, ADCMC of SFV-infected cells was unlikely to contribute to the protection. At present we cannot distinguish between the other possibilities. Although the non-neutralizing antibodies raised by the peptides do bind to intact SFVinfected cells (Snijders et al., 1991) , it is still an open question whether these antibodies can actually bind to native virions. We found that serum viraemia 1 h after infection (before new virions can appear) was significantly reduced in mice that received antipeptide serum raised against keyhole limpet haemocyanin-coupled peptide d (data not shown). Hunt et al. (1991) report that peptide-induced antibodies that protect mice against another alphavirus, Venezuelan equine encephalomyelitis virus, bind to virus-infected ceils but are unable to bind native virions. These authors emphasize that the binding of non-neutralizing antibodies to virus-infected cells causes a slower production of virions. From the finding that the peptide-induced protection also requires the development of a neutralizing antibody response in the animal after infection, they conclude that the retardation of virus production allows the neutralizing antibodies raised after infection to contribute to that protection. In agreement with these observations, SFVneutralizing antibodies were indeed detected in the postchallenge sera of surviving peptide-immunized mice (Table 2) .
In theory, the SFV T h cell epitope in peptide f may have contributed directly to protection by priming an SFV-specific Th cell response that triggers an augmented neutralizing antibody response upon contact with the infectious virus. The effect of T cell priming was described previously among others by Milich et al. (1987) and Ertl et al. (1989) for synthetic Th cell epitopes of hepatitis B virus and rabies virus respectively. This T cell priming effect is thought to be based on the activation of T cells by the synthetic T cell site on antigen-presenting cells other than B cells. Upon subsequent contact with the whole virus, B cells that have taken up and processed the virus will present the same T cell site and will receive immediate help from the already activated T cells, resulting in an accelerated and enhanced secondary antibody production.
However, such a T cell-mediated mechanism will be only partially protective against SFV, since peptide c (which contains the same SFV T h cell epitope as peptidef but an inferior SFV B cell epitope) protected only 33 ~ of the peptide-immunized mice. This is in agreement with a recent report on a peptide with a Th cell epitope from rabies virus (Ertl et al., 1989) . Although inoculation with this peptide resulted in an accelerated and enhanced neutralizing antibody response upon booster immunization with inactivated rabies virus, peptide-immunized mice were not protected. Both for SFV and for rabies virus, these data can be explained by the observation that passively transferred neutralizing antibodies have to be given within 2 days of inoculation with live virus to prevent lethal infection (Ertl et al., 1989; Boere et al., 1985) , whereas the augmented neutralizing antibody response is demonstrable only after 5 days (Ertl et al., 1989) . A direct beneficial role of the Z h cell epitope in triggering an augmented antibody response upon contact with infectious virus is therefore only to be expected for viruses that have a longer incubation period.
In this study we show further by measuring the crossreactivity of antipeptide antibodies with different partially overlapping peptides, that peptides containing combinations of predefined B and T h cell epitopes evoked antibodies to not only the predefined B cell epitope but also to the predefined Th cell epitope of the peptide. This finding is explained by the fact that all residues in a small peptide including those of the T h cell epitope are at the surface, enabling contact with the immunoglobulin receptor on B cells. However, antibody responses that are directed to regions outside the predefined B cell epitope in the immunizing peptides are likely to be unreactive against the virus.
The ability of peptide f to induce SFV-reactive antibodies titres higher than that of peptide g contrasts with the finding that peptide g generally induced higher antipeptide titres (Tables 2 and 4) . Moreover, the influenza virus T h cell epitope present in peptide g is highly effective as a Z h cell epitope when combined with other B cell epitopes (Golvano et aL, 1990; Koolen et al., 1990) . Apart from the properties of the B and Th cell epitopes themselves, two factors have been reported to influence the titre and specificity of the peptide-induced antibody response: preferential pairing between B and T h cell epitopes (Manca et aL, 1985) and the orientation of these epitopes (Golvano et al., 1990; Cox et al., 1988) . Therefore, not every peptide containing a potentially protective B and Th cell epitope combination induces antibodies with the specificity required for protection (Francis et al., 1987) . The importance of epitope orientation for the antibody response was confirmed by the results with a peptide that contained the same B and T h cell epitopes as peptide f (Table 1) , but in a reversed orientation (B-T). This peptide induced higher antibody titres to the T h cell epitope part of the peptide than to the predefined B cell epitope, and induced no detectable levels of SFV-reactive antibodies (I. Fernandez, personal communication) . In contrast, peptide c (Table 1) , also having a reversed orientation compared to peptidefand the same T h cell epitope, primarily induced antibodies to its predefined B cell epitope. These results show that more research is needed to establish the rules that govern the specificities of the antibodies induced by synthetic B and Th cell epitope combinations. To establish these rules is especially important in view of the development of synthetic peptide vaccines with multiple Th cell epitopes for different major histocompatibility complex phenotypes.
In conclusion, a fully synthetic peptide containing a predefined B and Th cell epitope of SFV protected H-2 d mice effectively against SFV by inducing high titres of non-neutralizing SFV-reactive antibodies. This peptide was superior in protection compared to a peptide with the same SFV B cell epitope and a foreign Th cell epitope, because the former induced higher SFV-reactive antibody titres. Our results indicate that the Th cell epitope played an important role in protection against SFV by influencing the titre of protective antibodies, whereas the protective effect of priming a virus-specific Th cell response proved only marginal.
